Article
Decitabine induces IRF7-mediated immune responses in p53-mutated triple-negative breast cancer: a clinical and translational study.
Frontiers of medicine - 1 Apr 2024
Wang Haoyu, Wang Zhengyuan, Wang Zheng, Li Xiaoyang, Li Yuntong, Yan Ni, Wu Lili, Liang Ying, Wu Jiale, Song Huaxin, Qu Qing, Huang Jiahui, Chang Chunkang, Shen Kunwei, Chen Xiaosong, Lu Min
Abstract excerpt
p53 is mutated in half of cancer cases. However, no p53-targeting drugs have been approved. Here, we reposition decitabine for triple-negative breast cancer (TNBC), a subtype with frequent p53 mutations and extremely poor prognosis. In a retrospective study on tissue microarrays with 132 TNBC cases, DNMT1 overexpression was associated with p53 mutations (P = 0.037) and poor overall survival (OS) (P = 0.010). In a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.